Gene Expression Regulation, Leukemic
"Gene Expression Regulation, Leukemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
| Descriptor ID |
D015973
|
| MeSH Number(s) |
G05.308.370.500
|
| Concept/Terms |
Gene Expression Regulation, Leukemic- Gene Expression Regulation, Leukemic
- Regulation of Gene Expression, Leukemic
- Regulation, Gene Expression, Leukemic
- Leukemic Gene Expression Regulation
|
Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Leukemic".
Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Leukemic".
This graph shows the total number of publications written about "Gene Expression Regulation, Leukemic" by people in this website by year, and whether "Gene Expression Regulation, Leukemic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 6 | 6 |
| 2017 | 1 | 3 | 4 |
| 2018 | 2 | 5 | 7 |
| 2019 | 1 | 5 | 6 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2024 | 0 | 4 | 4 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gene Expression Regulation, Leukemic" by people in Profiles.
-
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021 07 08; 138(1):71-85.
-
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. 2019 03; 38(13):2241-2262.
-
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017 06 22; 129(25):3352-3361.
-
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 08 18; 128(7):971-81.
-
Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol. 2016 08; 44(8):740-4.
-
Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. Br J Haematol. 2015 Sep; 170(5):704-18.
-
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 2015 May; 169(3):344-51.
-
Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014 Nov; 167(3):376-84.
-
The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. Haematologica. 2014 Oct; 99(10):1591-8.
-
The protein phosphatase 2A regulatory subunit B55a is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta. 2014 Sep; 1843(9):1969-77.